Ablation of glucagon receptor signaling by peptide-based glucagon antagonists improves glucose tolerance in high fat fed mice.

LM McShane, ZJ Franklin, Finbarr O'Harte, Nigel Irwin

Research output: Contribution to journalArticle

Abstract

Modification to the structure of glucagon has provided a number of glucagon receptor antagonists with possible therapeutic application for diabetes. These novel peptide analogs include desHis(1)Pro(4)Glu(9)-glucagon and desHis(1)Pro(4)Glu(9)(Lys(30)PAL)-glucagon. This study has evaluated the metabolic benefits of once daily administration of desHis(1)Pro(4)Glu(9)-glucagon and desHis(1)Pro(4)Glu(9)(Lys(30)PAL)-glucagon in high fat (45%) fed mice for 15 days. Administration of desHis(1)Pro(4)Glu(9)-glucagon and desHis(1)Pro(4)Glu(9)(Lys(30)PAL)-glucagon had no significant effect on body weight, food intake or circulating glucose concentrations during the treatment period. However, both peptides significantly (P
LanguageEnglish
Pages95-101
JournalPeptides
Volume60
DOIs
Publication statusPublished - 18 Aug 2014

Fingerprint

Glucagon Receptors
Ablation
Glucagon
Fats
Glucose
Peptides
Medical problems
Eating
Body Weight
deshistidyl(1)-prolyl(4)-glutamyl(9)-glucagon

Cite this

@article{83fa2d5866174850b1bbc6833c750c7d,
title = "Ablation of glucagon receptor signaling by peptide-based glucagon antagonists improves glucose tolerance in high fat fed mice.",
abstract = "Modification to the structure of glucagon has provided a number of glucagon receptor antagonists with possible therapeutic application for diabetes. These novel peptide analogs include desHis(1)Pro(4)Glu(9)-glucagon and desHis(1)Pro(4)Glu(9)(Lys(30)PAL)-glucagon. This study has evaluated the metabolic benefits of once daily administration of desHis(1)Pro(4)Glu(9)-glucagon and desHis(1)Pro(4)Glu(9)(Lys(30)PAL)-glucagon in high fat (45{\%}) fed mice for 15 days. Administration of desHis(1)Pro(4)Glu(9)-glucagon and desHis(1)Pro(4)Glu(9)(Lys(30)PAL)-glucagon had no significant effect on body weight, food intake or circulating glucose concentrations during the treatment period. However, both peptides significantly (P",
author = "LM McShane and ZJ Franklin and Finbarr O'Harte and Nigel Irwin",
year = "2014",
month = "8",
day = "18",
doi = "10.1016/j.peptides.2014.08.002",
language = "English",
volume = "60",
pages = "95--101",
journal = "Peptides",
issn = "0196-9781",
publisher = "Elsevier",

}

Ablation of glucagon receptor signaling by peptide-based glucagon antagonists improves glucose tolerance in high fat fed mice. / McShane, LM; Franklin, ZJ; O'Harte, Finbarr; Irwin, Nigel.

In: Peptides, Vol. 60, 18.08.2014, p. 95-101.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Ablation of glucagon receptor signaling by peptide-based glucagon antagonists improves glucose tolerance in high fat fed mice.

AU - McShane, LM

AU - Franklin, ZJ

AU - O'Harte, Finbarr

AU - Irwin, Nigel

PY - 2014/8/18

Y1 - 2014/8/18

N2 - Modification to the structure of glucagon has provided a number of glucagon receptor antagonists with possible therapeutic application for diabetes. These novel peptide analogs include desHis(1)Pro(4)Glu(9)-glucagon and desHis(1)Pro(4)Glu(9)(Lys(30)PAL)-glucagon. This study has evaluated the metabolic benefits of once daily administration of desHis(1)Pro(4)Glu(9)-glucagon and desHis(1)Pro(4)Glu(9)(Lys(30)PAL)-glucagon in high fat (45%) fed mice for 15 days. Administration of desHis(1)Pro(4)Glu(9)-glucagon and desHis(1)Pro(4)Glu(9)(Lys(30)PAL)-glucagon had no significant effect on body weight, food intake or circulating glucose concentrations during the treatment period. However, both peptides significantly (P

AB - Modification to the structure of glucagon has provided a number of glucagon receptor antagonists with possible therapeutic application for diabetes. These novel peptide analogs include desHis(1)Pro(4)Glu(9)-glucagon and desHis(1)Pro(4)Glu(9)(Lys(30)PAL)-glucagon. This study has evaluated the metabolic benefits of once daily administration of desHis(1)Pro(4)Glu(9)-glucagon and desHis(1)Pro(4)Glu(9)(Lys(30)PAL)-glucagon in high fat (45%) fed mice for 15 days. Administration of desHis(1)Pro(4)Glu(9)-glucagon and desHis(1)Pro(4)Glu(9)(Lys(30)PAL)-glucagon had no significant effect on body weight, food intake or circulating glucose concentrations during the treatment period. However, both peptides significantly (P

U2 - 10.1016/j.peptides.2014.08.002

DO - 10.1016/j.peptides.2014.08.002

M3 - Article

VL - 60

SP - 95

EP - 101

JO - Peptides

T2 - Peptides

JF - Peptides

SN - 0196-9781

ER -